You are here: Industry Insights > Market News > J&J single-dose COVID-19 vaccine gets approval for EUA in India

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:70500-72-0

Brexpiprazole CAS:913611-97-9

3-BROMOPHENANTHRENE

2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE

3-BROMO-4-FLUOROBIPHENYL

9-TRIFLUOROACETYLANTHRACENE

J&J single-dose COVID-19 vaccine gets approval for EUA in India

expresspharmaAugust 09, 2021

Tag: J&J , EUA , COVID-19 , India

Favorites

“Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India,” tweeted Union Health Minister, Mansukh Mandaviya last week.

J&J single-dose COVID-19 vaccine gets approval for EUA in India

The company had applied last week for the Emergency Use Authorisation (EUA) of its single-dose COVID-19 vaccine in India.

“Now India has five EUA vaccines. This will further boost nation’s collective fight against COVID-19,” the tweet further informed.

The EUA submission is based on topline efficacy and safety data from the phase-III ENSEMBLE clinical trial, which demonstrated that the company’s single-shot vaccine was 85 per cent effective in preventing the disease across all regions studied.

Previous:Pharma cos foray into digital healthcare to bolster personalised care in India: GlobalData

Next:Government increases JAK storeowners’ incentive from Rs 2.50 lakhs to up to Rs 5 lakhs

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

J&J single-dose COVID-19 vaccine gets approval for EUA in India | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

J&J single-dose COVID-19 vaccine gets approval for EUA in India

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

J&J single-dose COVID-19 vaccine gets approval for EUA in India

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>